Crystal-induced activation of the inflammasome: Gout and pseudogout;Kristallinduzierte Inflammasomaktivierung: Gicht und Pseudogicht

Zeitschrift fur Rheumatologie

Volumn 68, Issue 9, 2009, Pages 733-739

  Winzer, M ^a   Tausche, A K ^a   Aringer, M ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Gout; Inflammasome; Interleukin 1; Metabolic syndrome; Uric acid

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; URIC ACID;

DIET THERAPY; DRUG HYPERSENSITIVITY; GOUT; HUMAN; HYPERURICEMIA; INNATE IMMUNITY; KIDNEY FAILURE; PSEUDOGOUT; REVIEW; URIC ACID URINE LEVEL;

ANTI-INFLAMMATORY AGENTS; CYTOKINES; GOUT; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; IMMUNOLOGIC FACTORS; MODELS, IMMUNOLOGICAL; URIC ACID;

EID: 70450257817     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-009-0489-4     Document Type: Review

References (30)

1. Martinon F, Petrilli V, Mayor A et al (2006) Gout-associated uric acid crystals activate the N ALP3 inflammasome. Nature 440:237-241 (Pubitemid 43372104)
2. Ye Z, Ting JP (2008) NLR, the nucleotide-binding domain leucine-rich repeat containing gene family. Curr Opin Immunol 20:3-9
3. Arend WP, PalmerG, Gabay C (2008) IL-I, IL-18and IL-33 families of cytokines. Immunol Rev 223:2038
4. Martinon F. Tschopp J (2007) Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ 14:10-22 (Pubitemid 44911890)
5. Shi Y, Evans JE, Rock KL (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425:516-521 (Pubitemid 37237047)
6. Cassei SL, Eisenbarth SC, Iyer SS et al (2008) The Nalp3 inflammasome is essential for the development of silicosis. Proc Natl Acad Sci USA 105:9035-9040
7. Eisenbarth SC, Colegio OR, O'Connor W et al (2008) Crucial role for the Nalp3 inflammasome in the Immunostimulatory properties of aluminium adjuvants. Nature 453:1122-1126
8. Halle A, Hornung V, Petzold GC et al (2008) The NALP3 Inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 9:857-865
9. Martin WJ, Walton M, Harper J (2009) Resident macrophages initiating and driving inflammation In a monosodium urate monohydrate crystal-induced murine peritoneal model of acute gout. Arthritis Rheum 60:281-289
10. Schlesinger N, NorquistJM, Watson DJ (2009) Serum urate during acute gout. J Rheumatol 36:1287-1289
11. Zhang W, Doherty M, Pascual E et al (2006) EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65:1301-1311 (Pubitemid 44641591)
12. Tausche AK, Richter K, Grassler A et al (2004) Severe gouty arthritis refractory to anti-inflammatory drugs: treatment with anti-tumour necrosis factor alpha as a new therapeutic option. Ann Rheum Dis 63:1351-1352 (Pubitemid 39273525)
13. Fiehn C, Zeier M (2006) Successful treatment of chronic tophaceous gout with Infliximab (Remicade). Rheumatol Int 26:274-276 (Pubitemid 41830989)
14. Torres R, Macdonald L, Croll SD et al (2009) Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by IL-1 Inhibition in a novel animal model of gouty arthritis. Ann Rheum Dis 68:1517-1519
15. So A, De SmedtT, Revaz S, Tschopp J (2007) A pilot study of IL-1 Inhibition by anakinra in acute gout. Arthritis Res Ther 9:28 (Pubitemid 46511126)
16. Aringer M, Graessler J (2008) Understanding deficient elimination of uric add. Lancet 372:1929-1930
17. Enomoto A, Kimura H, Chairoungdua A et al (2002) Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417:447-452 (Pubitemid 34563537)
18. Graessler J, Graessler A, Unger S et al (2006) Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum 54:292-300 (Pubitemid 43124109)
19. Doring A, Gieger C, Mehta D et al (2008) SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet 40:430-436
20. Vitart V, Rudan I, Hayward C et al (2008) SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 40:437-442
21. Dehghan A, Kottgen A, Yang Q et al (2008) Association of three genetic loci with uric add concentration and risk of gout: a genome-wide association study. Lancet 372:1953-1961
22. Schumacher HRJr, Becker MA, Wortmann RL et al (2008) Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 59:1540-1548
23. Becker MA, Schumacher HR, MacDonald PA et al (2009) Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 36:1273-1282
24. Harrold LR, Andrade SE, Briesacher BA et al (2009) Adherence with urate-lowering therapies for the treatment of gout. Arthritis ResTher 11:46
25. Annemans L, Spaepen E, Gaskin M et al (2008) Gout in the UK and Germany: prevalence, comorbidities and management In general practice 2000-2005. Ann Rheum Dis 67:960-966 (Pubitemid 351956658)
26. Choi HK, Ford ES, Li C, Curhan G (2007) Prevalence of the metabolic syndrome in patients with gout: theThird National Health and Nutrition Examination Survey. Arthritis Rheum 57:109-115 (Pubitemid 46256732)
27. Kim SY, Guevara JP, Kim KM et al (2009) Hyperuricemia and risk of stroke: A systematic review and meta-analysis. Arthritis Rheum 61:885-892
28. Muir SW, Harrow C, Dawson J et al (2008) Allopurinol use yields potentially beneficial effects on inflammatory indices in those with recent ischemic stroke: a randomized, double-blind, placebo-controlled trial. Stroke 39:3303-3307
29. Williams CJ, Zhang Y, Timms A et al (2002) Autosomal dominant familial calcium pyrophosphate dihydrate deposition disease is caused by mutation in the transmembrane protein ANKH. Am J Hum Genet 71:985-991 (Pubitemid 135750532)
30. Maldonado I, Reginato AM, Reginato AJ (2001 ) Familial calcium crystal diseases: what have we learned? Curr Opin Rheumatol 13:225-233